Literature DB >> 21461636

MIR221/MIR222-driven post-transcriptional regulation of P27KIP1 and P57KIP2 is crucial for high-glucose- and AGE-mediated vascular cell damage.

G Togliatto1, A Trombetta1, P Dentelli1, A Rosso1, M F Brizzi2.   

Abstract

AIMS/HYPOTHESIS: MicroRNAs (miRNAs) are a novel group of small non-coding RNAs that regulate gene expression at the post-transcriptional level and act on their target mRNAs in a tissue- and cell-type-specific manner. Herein, the relevance of MIR221/MIR222 in high-glucose- and AGE-mediated vascular damage was investigated.
METHODS: Functional studies were performed using human mature endothelial cells and endothelial progenitor cells subjected to high glucose or AGE. Quantitative real-time amplification was performed to analyse MIR221/MIR222 expression in these experimental conditions. Luciferase assay was used to identify MIR221/MIR222 targets. Functional studies were performed in vitro and in vivo in mice using gain- and loss-of-function approaches.
RESULTS: Using an in vivo mouse model we demonstrated that exposure to AGE and high glucose impaired vessel formation. Moreover, in vitro functional studies revealed that both high glucose and AGE inhibit cell-cycle progression by modulating the expression of P27KIP1 (also known as CDKN1B) and P57KIP2 (also known as CDKN1C), which encode cyclin-dependent kinase inhibitor 1B (p27, Kip1) (P27KIP1) and cyclin-dependent kinase inhibitor 1C (p57, Kip2) (P57KIP2), respectively. Crucial to AGE- and high-glucose-mediated cell-cycle arrest was the downregulation of MIR221/MIR222 expression. Luciferase assay showed that MIR221 and MIR222 specifically bind to the P27KIP1 and P57KIP2 mRNA 3'-untranslated regions, implicating P27KIP1 and P57KIP2 as MIR221/MIR222 targets. These results were confirmed by gain-of-function experiments in vitro, and by injecting mice with endothelial cells overexpressing MIR221 and MIR222. CONCLUSIONS/
INTERPRETATION: We provide evidence that high-glucose- and AGE-induced inhibition of vascular cell proliferation is controlled by MIR221/MIR222-driven post-transcriptional regulation of P27KIP1 and P57KIP2. These data add further insight to the possible contribution of miRNAs in vascular damage mediated by a high-glucose environment.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21461636     DOI: 10.1007/s00125-011-2125-5

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  45 in total

1.  MicroRNAs modulate the angiogenic properties of HUVECs.

Authors:  Laura Poliseno; Andrea Tuccoli; Laura Mariani; Monica Evangelista; Lorenzo Citti; Keith Woods; Alberto Mercatanti; Scott Hammond; Giuseppe Rainaldi
Journal:  Blood       Date:  2006-07-18       Impact factor: 22.113

Review 2.  CDK inhibitors: cell cycle regulators and beyond.

Authors:  Arnaud Besson; Steven F Dowdy; James M Roberts
Journal:  Dev Cell       Date:  2008-02       Impact factor: 12.270

Review 3.  Clinical review: The role of advanced glycation end products in progression and complications of diabetes.

Authors:  Su-Yen Goh; Mark E Cooper
Journal:  J Clin Endocrinol Metab       Date:  2008-01-08       Impact factor: 5.958

4.  Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals.

Authors:  Mervin C Yoder; Laura E Mead; Daniel Prater; Theresa R Krier; Karim N Mroueh; Fang Li; Rachel Krasich; Constance J Temm; Josef T Prchal; David A Ingram
Journal:  Blood       Date:  2006-10-19       Impact factor: 22.113

5.  High glucose impairs early and late endothelial progenitor cells by modifying nitric oxide-related but not oxidative stress-mediated mechanisms.

Authors:  Yung-Hsiang Chen; Shing-Jong Lin; Feng-Yen Lin; Tao-Cheng Wu; Chen-Rong Tsao; Po-Hsun Huang; Po-Len Liu; Yuh-Lien Chen; Jaw-Wen Chen
Journal:  Diabetes       Date:  2007-03-26       Impact factor: 9.461

6.  Induction of aldose reductase in cultured human microvascular endothelial cells by advanced glycation end products.

Authors:  N Nakamura; H Obayashi; M Fujii; M Fukui; K Yoshimori; M Ogata; G Hasegawa; H Shigeta; Y Kitagawa; T Yoshikawa; M Kondo; M Ohta; M Nishimura; T Nishinaka; C Y Nishimura
Journal:  Free Radic Biol Med       Date:  2000-07-01       Impact factor: 7.376

7.  Regulation of p27Kip1 by miRNA 221/222 in glioblastoma.

Authors:  Jana K Gillies; Ian A J Lorimer
Journal:  Cell Cycle       Date:  2007-05-31       Impact factor: 4.534

Review 8.  MicroRNAs: opening a new vein in angiogenesis research.

Authors:  Jason E Fish; Deepak Srivastava
Journal:  Sci Signal       Date:  2009-01-06       Impact factor: 8.192

Review 9.  Role of microRNAs in vascular diseases, inflammation, and angiogenesis.

Authors:  Carmen Urbich; Angelika Kuehbacher; Stefanie Dimmeler
Journal:  Cardiovasc Res       Date:  2008-06-11       Impact factor: 10.787

10.  Global microRNA expression profiles in insulin target tissues in a spontaneous rat model of type 2 diabetes.

Authors:  B M Herrera; H E Lockstone; J M Taylor; M Ria; A Barrett; S Collins; P Kaisaki; K Argoud; C Fernandez; M E Travers; J P Grew; J C Randall; A L Gloyn; D Gauguier; M I McCarthy; C M Lindgren
Journal:  Diabetologia       Date:  2010-03-03       Impact factor: 10.122

View more
  34 in total

Review 1.  Metabolic stress in the myocardium: adaptations of gene expression.

Authors:  Peter A Crawford; Jean E Schaffer
Journal:  J Mol Cell Cardiol       Date:  2012-06-21       Impact factor: 5.000

2.  Insights into the molecular mechanisms of diabetes-induced endothelial dysfunction: focus on oxidative stress and endothelial progenitor cells.

Authors:  Mohamed I Saad; Taha M Abdelkhalek; Moustafa M Saleh; Maher A Kamel; Mina Youssef; Shady H Tawfik; Helena Dominguez
Journal:  Endocrine       Date:  2015-08-14       Impact factor: 3.633

Review 3.  Pathogenesis of diabetic cerebral vascular disease complication.

Authors:  Ren-Shi Xu
Journal:  World J Diabetes       Date:  2015-02-15

Review 4.  Diabetes-associated macrovascular complications: cell-based therapy a new tool?

Authors:  Maddalena Gili; Alberto Orsello; Sara Gallo; Maria Felice Brizzi
Journal:  Endocrine       Date:  2013-03-30       Impact factor: 3.633

Review 5.  Endothelial microRNAs and atherosclerosis.

Authors:  Xinghui Sun; Nathan Belkin; Mark W Feinberg
Journal:  Curr Atheroscler Rep       Date:  2013-12       Impact factor: 5.113

Review 6.  MicroRNAs mediate metabolic stresses and angiogenesis.

Authors:  Francesca Patella; Giuseppe Rainaldi
Journal:  Cell Mol Life Sci       Date:  2011-08-14       Impact factor: 9.261

7.  A diabetic milieu promotes OCT4 and NANOG production in human visceral-derived adipose stem cells.

Authors:  P Dentelli; C Barale; G Togliatto; A Trombetta; C Olgasi; M Gili; C Riganti; M Toppino; M F Brizzi
Journal:  Diabetologia       Date:  2012-10-12       Impact factor: 10.122

Review 8.  MicroRNAs: potential mediators and biomarkers of diabetic complications.

Authors:  Mitsuo Kato; Nancy E Castro; Rama Natarajan
Journal:  Free Radic Biol Med       Date:  2013-06-12       Impact factor: 7.376

9.  miR-221/222 control luminal breast cancer tumor progression by regulating different targets.

Authors:  Patrizia Dentelli; Matteo Traversa; Arturo Rosso; Gabriele Togliatto; Cristina Olgasi; Caterina Marchiò; Paolo Provero; Antonio Lembo; Giulia Bon; Laura Annaratone; Anna Sapino; Rita Falcioni; Maria Felice Brizzi
Journal:  Cell Cycle       Date:  2014-04-15       Impact factor: 4.534

10.  microRNAs Distinctively Regulate Vascular Smooth Muscle and Endothelial Cells: Functional Implications in Angiogenesis, Atherosclerosis, and In-Stent Restenosis.

Authors:  Gaetano Santulli
Journal:  Adv Exp Med Biol       Date:  2015       Impact factor: 2.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.